
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
Which CAR-based strategies would you consider to treat severe refractory #SLE based on data presented at #EULAR2025? @RheumNow

Aurelie Najm AurelieRheumo
3 months ago
POETYK PsA-1
Deucravacitinib TYK2i RCT Ph 3
ACR 20 DEU 54% vs. 34% PBO wk 16
ACR 50 DEU 23% vs. 14% PBO
also significant diff for HAQ-DI PASI 75 SF-36 PCS and MDA
Less Rx progression
@RheumNow #EULAR2025 LB0001 https://t.co/oRLlHwI4Bh


David Liew drdavidliew
3 months ago
Why do we need RA treatment recommendation updates? We keep on getting new data, for our keystone disease
so today Josef Smolen and colleagues present the new 2025 EULAR recommendations
#EULAR2025 @RheumNow https://t.co/OdHL8CAIKv


Janet Pope Janetbirdope
3 months ago
#ClinicalPearls
For
#cartilage #swelling in #relapsing #polychrondritis
Ask for #pics
#Levamisole in #cocaine
#infection - uncommon - from piercing
Acute #bacterial v chronic
#lymphoma
#malignancy
#vasculitis
#Trauma
Hx, duration, fever can be helpful
#EULAR2025
@RheumNow https://t.co/X2b6VHYsYa


Aurelie Najm AurelieRheumo
3 months ago
RCT of a digital intervention in RMDs? It was long awaited, and all the lights are green🟢!
German national Bechterew-App RCT of
App based intervention AXIA, control group was standard of care
200pts 12wks
ASAS20 response 51% vs. 9%
ASAS40 response rate 23% vs. 3%
BASDAI:

Janet Pope Janetbirdope
3 months ago
1st #recommendations for
#Hemochromatosis #arthropathy
#psuedogout
#CPPD
#calcium #pyrophosphate #arthritis
#EULAR2025 #Recommenadations II
@RheumNow @eular_org https://t.co/AnE4T2wYoa


Jiha Lee JihaRheum
3 months ago
67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them.
✅ Only 13% linked SLE control to CVD risk
🚫 0% picked correct BP/statin use in RA/AS/PsA
Barriers? Time, knowledge, and local guideline gaps.
POS0410-HPR @RheumNow #EULAR2025

Nelly ZIADE 🍀 Nellziade
3 months ago
#Relapsing_Polychondritis
Main differential diagnosis is GPA
🔺️No ANCA and no renal involvement in relapsing polychondritis
@Lupusreference
#EULAR2025
@RheumNow https://t.co/QUJZ3EDjj3


David Liew drdavidliew
3 months ago
“That is why this task force continues to say: nothing is better than methotrexate and glucocorticoids to start”
- Josef Smolen, on RA treatment
#EULAR2025 @RheumNow https://t.co/AbkgWS8tvH


David Liew drdavidliew
3 months ago
The key changes for the new 2025 EULAR recommendations on RA treatment
#EULAR2025 @RheumNow https://t.co/dp5LnoFdpW


Janet Pope Janetbirdope
3 months ago
#EULAR new #RA #recommendations
J Smolen presents justification for
#MTX +#glucocorticoids at onset
do you agree?
Diff from #ACR
#EULAR #Recommendations II
#EULAR2025 @RheumNow https://t.co/wqCX5HA87q


Aurelie Najm AurelieRheumo
3 months ago
URAT1 inhibitors look like the way to go in Gout!
Presented in multiple abstracts at #EULAR2025
Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300
Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302
Ph 2b RCT of SAP-001 Refractory Gout +/-

Nelly ZIADE 🍀 Nellziade
3 months ago
EULAR Points to consider for the definition of #D2M #Psoriatic_Arthritis
1️⃣ Failure >= 2 b/tsDMARDs with >=2 different MOA
2️⃣ Perceived as problematic
3️⃣ Evidence of persistent disease (active disease, EMM, inflammation)
#EULAR2025
@RheumNow https://t.co/69nFEYntF0


Nelly ZIADE 🍀 Nellziade
3 months ago
EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis
#D2M
1️⃣ Failure >= 2 b/tsDMARDs
2️⃣ Problematic
3️⃣ Evidence of persistent disease (inflammation is mandatory)
+
4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI
#EULAR2025
@RheumNow https://t.co/8nx26mWX3C


David Liew drdavidliew
3 months ago
@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains.
Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for
#EULAR2025 @RheumNow https://t.co/fIxHRGDFcK
